<\/p>\n
Aldactone<\/strong> er en 25 \/ 50 \/ 100 mg spironolactone tablet<\/strong> from RPG Life Sciences — a mineralocorticoid receptor antagonist (aldosterone antagonist)<\/strong> der virker p\u00e5 mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone. Half-life 1.4 hours (parent); 16-24 hours (active metabolites canrenone and 7-\u03b1-thiomethylspirolactone); onset 24-48 hours (needs time for receptor antagonism to manifest at the tissue level); peak effect 2-3 days; duration 2-3 days after discontinuation. Primary indication: heart failure with reduced ejection fraction (HF-REF), primary aldosteronism, resistant hypertension, cirrhotic ascites, adjunct treatment for hirsutism and PCOS<\/strong>. Typisk dosering: Resistent hypertension<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Ikke et f\u00f8rstelinje antihypertensivt middel.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg. Key contraindications: see full list below. Monitor electrolytes, creatinine, and glucose. Kombiner ikke med lithium<\/strong> (thiazid-\/loop-diuretika kan fremskynde lithiumtoksicitet). Brug under graviditet er tilf\u00e6ldesspecifik<\/strong> (se graviditetsnote). For de fleste hypertensionspatienter virker diuretika bedst som andet eller tredje middel<\/strong> \u2014 typisk kombineret med en ARB, ACE-h\u00e6mmer eller calciumkanalblokerer snarere end brugt alene.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n Aldactone is an oral 25 \/ 50 \/ 100 mg spironolactone tablet from RPG Life Sciences, supplied in 30-180 tablets. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone.<\/p>\n Spironolactone inhibits the mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. De nedstr\u00f8mmende effekter:<\/p>\n Afg\u00f8rende kliniske fors\u00f8gsresultater:<\/strong> RALES (1999)<\/strong> — landmark trial of spironolactone 25-50 mg in severe HF-REF; 30% reduction in all-cause mortality. Established aldosterone antagonism as standard HF-REF therapy. EPHESUS<\/strong> og EMPHASIS-HF<\/strong> extended to eplerenone. PATHWAY-2 (2015)<\/strong> — spironolactone 25-50 mg was the most effective fourth agent for resistant hypertension vs bisoprolol or doxazosin. TOPCAT<\/strong> — modest benefit in HF with preserved ejection fraction (HF-PEF); signal stronger in Americas arm than Russia arm (controversial).<\/p>\n Heart dose:<\/strong> Resistent hypertension<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Ikke et f\u00f8rstelinje antihypertensivt middel.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg.<\/p>\n Andre indikationer:<\/strong> Heart failure with reduced ejection fraction (EF ≤35%):<\/strong> 12.5-25 mg once daily; target 25-50 mg if tolerated (RALES trial). Leverskrumpe med ascites:<\/strong> 50-400 mg\/day, usually with furosemide 20-160 mg (1:2.5 ratio); target 0.5 kg\/day weight loss. Hirsutism \/ PCOS \/ acne (female patients):<\/strong> 50-200 mg\/day — suppresses androgen-driven hair growth and acne over 3-6 months (off-label but well-established).<\/p>\n Administration:<\/strong> \u00e9n gang dagligt (eller to gange dagligt for h\u00f8j dosis loop-diuretika ved HF), om morgenen. Aftendosering for\u00e5rsager nokturi og b\u00f8r undg\u00e5s n\u00e5r muligt. Tag p\u00e5 samme tidspunkt hver dag. Mad p\u00e5virker ikke absorptionen markant for nogen af disse diuretika.<\/p>\n Overv\u00e5gningsplan:<\/strong><\/p>\n Oph\u00f8r:<\/strong> ingen abstinenssyndrom, men pludselig stop kan for\u00e5rsake rebound-volumenretention hos HF-patienter p\u00e5 kronisk h\u00f8j dosis loop-diuretika \u2014 trapp ned hvor muligt og overv\u00e5g v\u00e6gt.<\/p>\n Almindelige (>1%):<\/strong><\/p>\n Ikke almindelige, men klinisk vigtige:<\/strong><\/p>\n Graviditet:<\/strong> absolut kontraindiceret<\/strong> — anti-androgen activity causes feminisation of male fetuses.<\/p>\n Amning:<\/strong> generelt acceptabelt i lave doser; h\u00f8je doser kan h\u00e6mme laktation (is\u00e6r thiazider). Alternative antihypertensiva (propranolol, nifedipin) foretr\u00e6kkes, n\u00e5r muligt.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Aldactone?<\/h2>\n
How Spironolactone Works<\/h2>\n
\n
Godkendte og evidensbaserede anvendelser<\/h2>\n
\n
Aldactone Dosage<\/h2>\n
\n
\n
Bivirkninger<\/h2>\n
\n
\n
Kontraindikationer<\/h2>\n
\n
L\u00e6gemiddelinteraktioner<\/h2>\n
\n
Where Aldactone Fits in the Diuretic Class<\/h2>\n